NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06911112
This study is recruiting at 12 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Major Depressive Disorder
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Neurocrine Biosciences
- Last updated on ClinicalTrials.gov
- August 11, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Neurocrine Clinical Site · Huntsville, AL
Arkansas · 1
- Neurocrine Clinical Site · Bryant, AR
California · 3
- Neurocrine Clinical Site · Glendale, CA
- Neurocrine Clinical Site · Redlands, CA
- Neurocrine Clinical Site · San Francisco, CA
Florida · 2
- Neurocrine Clinical Site · Hollywood, FL
- Neurocrine Clinical Site · Tampa, FL
Georgia · 1
- Neurocrine Clinical Site · Atlanta, GA
New York · 1
- Neurocrine Clinical Site · New York, NY
Ohio · 1
- Neurocrine Clinical Site · Mason, OH
Texas · 1
- Neurocrine Clinical Site · DeSoto, TX
Virginia · 1
- Neurocrine Clinical Site · Charlottesville, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.